Dr. Lager’s research and clinical interests are focused on using clinical cytogenetic and molecular genetic modalities for the investigation and discovery of neoplasm-associated genetic abnormalities. She’s interested in employing sophisticated clinical laboratory diagnostics toward discovery of novel disease markers, and using these markers for patient prognosis and treatment stratification.
University of Wisconsin-Madison
Madison, WI
Fellowship - Clinical Molecular Genetics and Genomics
2018
University of Wisconsin-Madison
Madison, WI
Fellowship - Clinical Cytogenetics and Genomics
2017
Case Western Reserve University
Cleveland, OH
PhD - Genetics
2015
Characterization of chromosome 5 aberrations in TP53 mutated myeloid neoplasms with =5% blasts: An International TP53 Investigators Network (iTiN) study.
Characterization of chromosome 5 aberrations in TP53 mutated myeloid neoplasms with =5% blasts: An International TP53 Investigators Network (iTiN) study. Cancer. 2026 Jan 01; 132(1):e70210.
PMID: 41417597
Guidelines for the testing and reporting of cytogenetic results for risk stratification of multiple myeloma: a report of the Cancer Genomics Consortium Plasma Cell Neoplasm Working Group.
Guidelines for the testing and reporting of cytogenetic results for risk stratification of multiple myeloma: a report of the Cancer Genomics Consortium Plasma Cell Neoplasm Working Group. Blood Cancer J. 2025 Jun 18; 15(1):86.
PMID: 40533444
Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms.
Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms. Blood Cancer J. 2024 06 18; 14(1):99.
PMID: 38890297
Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis.
Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis. Blood Cancer Discov. 2024 May 01; 5(3):164-179.
PMID: 38150184
Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults.
Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults. Blood Adv. 2024 01 09; 8(1):164-171.
PMID: 38039510
Germline loss-of-function BRCA1 and BRCA2 mutations and risk of de novo hematopoietic malignancies.
Germline loss-of-function BRCA1 and BRCA2 mutations and risk of de novo hematopoietic malignancies. Haematologica. 2024 01 01; 109(1):351-356.
PMID: 37139596
Acute lymphoblastic leukemia with myeloid mutations is a high-risk disease associated with clonal hematopoiesis.
Acute lymphoblastic leukemia with myeloid mutations is a high-risk disease associated with clonal hematopoiesis. Blood Cancer Discov. 2023 Dec 27.
PMID: 38150184
Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults.
Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults. Blood Adv. 2023 Dec 01.
PMID: 38039510
Postmortem genetic testing in sudden unexplained death: A public health laboratory experience.
Postmortem genetic testing in sudden unexplained death: A public health laboratory experience. J Forensic Sci. 2023 Nov; 68(6):2065-2075.
PMID: 37614113
Germline loss of function BRCA1 and BRCA2 mutations and risk of de novo hematopoietic malignancies.
Germline loss of function BRCA1 and BRCA2 mutations and risk of de novo hematopoietic malignancies. Haematologica. 2023 May 04.
PMID: 37139596